Wilbur Asheld, DO
Nuclear Cardiology · West Islip, NYNPI 1710247549
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Esperion Therapeutics, Inc. accounts for 60.1% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2021 at $7,123 and has fallen 88.1% since, to $845 in 2025.
Across 141 payments — averaging $80.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$7K
- Abbott$946
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$841
- Novartis$687
- Merck$515
- Boston Scientific$495
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$6,36056%
- Food & beverage$4,77642%
- Education$1992%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 12 | $6,807 |
| Abbott | 16 | $946 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $841 |
| Novartis | 28 | $687 |
| Merck | 33 | $515 |
| Boston Scientific | 14 | $495 |
| Johnson & Johnson | 5 | $185 |
| Astellas Pharma US Inc | 2 | $180 |
| Edwards Lifesciences | 2 | $151 |
| Novo Nordisk | 1 | $114 |
| Medtronic | 2 | $93 |
| Cvrx, Inc. | 1 | $78 |
| Kestra Medical Technology Services, Inc. | 1 | $55 |
| Amgen | 2 | $37 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $28 |
| Orthofix Medical, Inc. | 2 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Pfizer | 1 | $18 |
| Abiomed | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$6,718
- NEXLETOL$6,718
- CARDIOMEMS$218
- AMPLATZER AMULET$165
- Farapulse$148
- CardioMEMS HF System$131
- Allure CRT Pacemaker$128
- XARELTO$123
- LifeVest$115
- Ozempic$114
- WATCHMAN Access System$108
How this compares
$11,335 in reported general payments places this provider in the 80th percentile of 21 nuclear cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 53 | $41,558 |
| EliquisApixaban | 16 | $22,007 |
| EntrestoSacubitril/Valsartan | 13 | $8,785 |
| Ezetimibe | 73 | $2,319 |
| Rosuvastatin Calcium | 145 | $2,118 |
| Metoprolol Succinate | 87 | $1,097 |
| Bumetanide | 25 | $723 |
| Atorvastatin Calcium | 47 | $635 |
| Valsartan | 17 | $328 |
| ClopidogrelClopidogrel Bisulfate | 22 | $323 |
| Amlodipine Besylate | 70 | $270 |
| Losartan Potassium | 25 | $148 |
| Ramipril | 12 | $114 |
| Carvedilol | 20 | $113 |
| Furosemide | 24 | $86 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $18 | $22,00716 claims |
| NovartisEntresto | $687 | $8,78513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 21 nuclear cardiology providers in New York.
Other nuclear cardiology in West Islip
- John AsheldWest Islip$24K
- Klaus RentropNew York$5.6M
- Diwakar JainHawthorne$105K
- Brian RiegelWilliamsville$23K
- Jonathan WeinsaftNew York$10K
- Ossama SamuelBrooklyn$7K
- Rajesh RohatgiGarden City$4K
- Harout YacoubNew York$2K
- Nicholas PapapietroBrooklyn$2K
- Ahmad Nawid LatifiRochester$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.